BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel) 2015;3:519-43. [PMID: 26350593 DOI: 10.3390/vaccines3030519] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Lin Y, Shen LY, Fu H, Dong B, Yang HL, Yan WP, Kang XZ, Dai L, Zhou HT, Yang YB, Liang Z, Chen KN. P21, COX-2, and E-cadherin are potential prognostic factors for esophageal squamous cell carcinoma. Dis Esophagus 2017;30:1-10. [PMID: 27868288 DOI: 10.1111/dote.12522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
2 Kalita P, Tripathi T. Methodological advances in the design of peptide-based vaccines. Drug Discovery Today 2022. [DOI: 10.1016/j.drudis.2022.03.004] [Reference Citation Analysis]
3 Wang X, Qi Y, Kong X, Zhai J, Li Y, Song Y, Wang J, Feng X, Fang Y. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. Cancer Lett 2019;442:409-28. [PMID: 30419345 DOI: 10.1016/j.canlet.2018.10.042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
4 Guryanova SV, Khaitov RM. Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine. Front Immunol 2021;12:607178. [PMID: 33959120 DOI: 10.3389/fimmu.2021.607178] [Reference Citation Analysis]
5 Hayes DA, Kunde DA, Taylor RL, Pyecroft SB, Sohal SS, Snow ET. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS One 2017;12:e0177919. [PMID: 28591206 DOI: 10.1371/journal.pone.0177919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Rodrigues-da-Silva RN, Correa-Moreira D, Soares IF, de-Luca PM, Totino PRR, Morgado FN, Oliveira Henriques MDG, Peixoto Candea AL, Singh B, Galinski MR, Moreno A, Oliveira-Ferreira J, Lima-Junior JDC. Immunogenicity of synthetic peptide constructs based on PvMSP9E795-A808, a linear B-cell epitope of the P. vivax Merozoite Surface Protein-9. Vaccine 2019;37:306-13. [PMID: 30509693 DOI: 10.1016/j.vaccine.2018.10.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
7 Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci 2016;7:842-54. [PMID: 28791117 DOI: 10.1039/c5sc03892h] [Cited by in Crossref: 244] [Cited by in F6Publishing: 119] [Article Influence: 34.9] [Reference Citation Analysis]
8 Zheng T, Wang A, Hu D, Wang Y. Tumor-targeting templated silica nanoparticles as a dual-drug delivery system for anti-angiogenic ovarian cancer therapy. Exp Ther Med 2017;14:2162-70. [PMID: 28962137 DOI: 10.3892/etm.2017.4777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
9 Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, Song J, Yang JM. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug Resist Updat. 2017;32:1-15. [PMID: 29145974 DOI: 10.1016/j.drup.2017.07.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
10 Ochnik AM, Baxter RC. Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer. Endocr Relat Cancer 2016;23:R513-36. [PMID: 27733416 DOI: 10.1530/ERC-16-0218] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
11 Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. Target Oncol 2017;12:571-97. [PMID: 28815409 DOI: 10.1007/s11523-017-0514-5] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 19.5] [Reference Citation Analysis]